Drug products: Abboticin, Abboticin Amdipharm, Abboticin®, Abboticin® Novum, Ery 500 mg, Ery-Max®, Erythro-base, Erythrocine, Erythromycin, Erythromycin Ebb, Erythromycin Panpharma
ATC code: J01FA01
Substances: erythromycin, erythromycin acistrate, erythromycin estolate, erythromycin ethyl carbonate, erythromycin ethylsuccinate, erythromycin gluceptate, erythromycin lactobionate, erythromycin propionate, erythromycin stearate, erythromycin stinoprate, erythromycin thiocyanate
Erythromycin is associated with QT-prolongation on ECG and thus a risk of potentially fatal arrhythmias of the type Torsade de pointes ventricular tachycardia. No difference in risk between men and women has been shown for erythromycin but a known risk factor for Torsade de pointes is female sex.
Erythromycin pharmacokinetics was examined after a single dose intravenous administration to healthy volunteers (12 men, 12 women; age 17-23 years). A small sex difference was found in total body clearance adjusted per kilogram bodyweight. The serum concentration-time profiles of erythromycin in men and women were not sufficiently different over the 7h to warrant dosage adjustment . No sex differentiation in dosing has been recommended by the pharmaceutical company .
During pregnancy, erythromycin blood concentration is decreased, due to increased volume of distribution and enhanced metabolism [3, 4].
A study showed that a four-day treatment with erythromycin 500 mg twice daily against chlamydia trachomatis infection was not better than seven-day treatment and the results were similar in men and women .A study found no association between occurrence of erythromycin resistance and the patient’s sex .
Erythromycin has been associated with prolonged QT-interval and a risk of Torsades de pointes ventricular tachycardia [2, 7-9]. Among the known risk factors of drug-induced ventricular arrhythmias are female sex, hypokalemia, bradycardia, and base line QT-prolongation .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2021-01-11
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson